CN / EN

Research Transformation

Industry Fund

Leading Early-Stage Value Investor in China's Healthcare Sector

BAHEAL ZHONGXIN CAPITAL currently has RMB 4 billion under management. Leveraging Baheal Pharma Group’s technology innovation and resource integration platform, BAHEAL ZHONGXIN CAPITAL focuses on investing in and incubating healthcare products and services with technological differentiation that can truly optimize clinical practice.

Early Stage

New and Innovative

Long-Term Commitment

Incubation Service

Pre-Investment Evaluation

Pre-Investment Evaluation

01

Project Initiation

Project Initiation

02

Preclinical Research

Preclinical Research

03

Clinical Trial Application (IND)

Clinical Trial Application (IND)

04

Clinical Research

Clinical Research

05

Approval

Approval

06

Post-Market Evaluation

Post-Market Evaluation

07

Baheal Sinovate

Through concentrating on end-to-end incubation process of original innovation pipelines, Baheal Sinovate delivers comprehensive full-lifecycle industrial empowerment based on its specialized and systematic incubation infrastructure. We foster seamless industry-academia collaboration to form a fully closed-loop value ecosystem.

Industrial Space

Clinical Medical Services

Digitalization Capability

Market Research

Capital Funding

Patent Management

Human Resources

R&D Project Management

...

Regulatory Registration Services

Cutting-Edge Collaboration